Iqvia (NYSE:IQV) Shares Pass Above Fifty Day Moving Average of $147.55

Shares of Iqvia Holdings Inc (NYSE:IQV) passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $147.55 and traded as high as $158.40. Iqvia shares last traded at $157.19, with a volume of 23,316 shares.

A number of equities research analysts have issued reports on IQV shares. Stifel Nicolaus set a $14.00 price target on Oasis Petroleum and gave the stock a “buy” rating in a research note on Wednesday, June 19th. William Blair reissued an “outperform” rating on shares of Iqvia in a report on Wednesday, June 19th. Wolfe Research assumed coverage on shares of Iqvia in a report on Tuesday, April 2nd. They set a “market perform” rating for the company. TheStreet downgraded shares of ZTO Express (Cayman) from a “b+” rating to a “c” rating in a report on Wednesday, May 1st. Finally, Leerink Swann assumed coverage on shares of Alder Biopharmaceuticals in a report on Tuesday, May 28th. They set an “outperform” rating and a $21.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Iqvia presently has an average rating of “Buy” and a consensus price target of $155.49.

The company has a debt-to-equity ratio of 1.69, a quick ratio of 1.14 and a current ratio of 1.14. The company’s fifty day moving average price is $148.02. The company has a market capitalization of $30.98 billion, a price-to-earnings ratio of 30.73, a P/E/G ratio of 1.93 and a beta of 0.87.

Iqvia (NYSE:IQV) last announced its quarterly earnings results on Wednesday, May 1st. The medical research company reported $1.53 EPS for the quarter, beating the Zacks’ consensus estimate of $1.41 by $0.12. Iqvia had a net margin of 2.35% and a return on equity of 15.08%. The firm had revenue of $2.68 billion during the quarter, compared to the consensus estimate of $2.67 billion. During the same quarter last year, the firm earned $1.34 EPS. The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. Equities analysts predict that Iqvia Holdings Inc will post 5.89 EPS for the current year.

In related news, insider Ari Bousbib sold 96,000 shares of the stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $160.00, for a total value of $15,360,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kevin C. Knightly sold 46,080 shares of the stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $138.06, for a total transaction of $6,361,804.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 238,080 shares of company stock valued at $36,121,805. 6.00% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in the stock. Securian Asset Management Inc lifted its holdings in shares of Iqvia by 0.5% in the 1st quarter. Securian Asset Management Inc now owns 16,374 shares of the medical research company’s stock valued at $2,355,000 after acquiring an additional 78 shares during the last quarter. Conning Inc. lifted its stake in Iqvia by 3.6% in the first quarter. Conning Inc. now owns 2,600 shares of the medical research company’s stock worth $374,000 after purchasing an additional 90 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in Iqvia by 1.2% in the first quarter. Louisiana State Employees Retirement System now owns 8,400 shares of the medical research company’s stock worth $1,208,000 after purchasing an additional 100 shares during the last quarter. Hall Laurie J Trustee lifted its stake in Iqvia by 26.3% in the first quarter. Hall Laurie J Trustee now owns 480 shares of the medical research company’s stock worth $69,000 after purchasing an additional 100 shares during the last quarter. Finally, Montag & Caldwell LLC lifted its stake in Iqvia by 4.1% in the first quarter. Montag & Caldwell LLC now owns 2,686 shares of the medical research company’s stock worth $386,000 after purchasing an additional 107 shares during the last quarter. 89.69% of the stock is owned by hedge funds and other institutional investors.

Iqvia Company Profile (NYSE:IQV)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read More: What is the Gross Domestic Product (GDP)?

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.